Key result
The TROICA study is a planned randomized trial of approximately 1000 patients to evaluate whether tenecteplase improves 30-day survival and hospital admission in out-of-hospital cardiac arrest.
Why the study?
Does tenecteplase improve 30-day survival and hospital admission in patients with out-of-hospital cardiac arrest of presumed cardiac origin?
RCT (n=1,000)
double-blind
randomized
Yes
Does tenecteplase improve 30-day survival and hospital admission in patients with out-of-hospital cardiac arrest of presumed cardiac origin?
No takes yet. Share an insight, caveat, or question.
The TROICA study protocol outlines a large randomized trial to evaluate the efficacy and safety of prehospital tenecteplase during resuscitation for out-of-hospital cardiac arrest.
Spöhr et al. (2005) conducted an RCT in out-of-hospital cardiac arrest (n=1,000). tenecteplase vs. placebo was evaluated on 30-day survival rate and hospital admission. The TROICA study is a planned randomized trial of approximately 1000 patients to evaluate whether tenecteplase improves 30-day survival and hospital admission in out-of-hospital cardiac arrest.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: